



Bill Summary
The Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009
(H.R.930/S. 571)

SECTION 1. SHORT TITLE

The Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act (PPARCCA)

SECTION 2. TABLE OF CONTENTS

Section 1. Short Title

Section 2. Table of Contents

Section 3. Findings

SECTION 3. FINDINGS

SECTION 4. EXPANSION OF BIOMEDICAL RESEARCH

- Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to continue to expand and intensify research on psoriasis and psoriatic arthritis.
- Directs NIAMS and National Institute of Allergy and Infectious Diseases (NIAID) to coordinate with other National Institutes of Health (NIH) centers, institutes and offices, with respect to psoriasis and psoriatic arthritis research.

SECTION 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY

- Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to undertake psoriasis and psoriatic arthritis data collection and develop a national psoriasis and psoriatic arthritis patient registry.

SECTION 6. NATIONAL SUMMIT

- Encourages the Department of Health and Human Services (HHS) to convene a summit on the federal government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit also should address psoriasis and psoriatic arthritis co-morbidities and should include myriad external stakeholders and federal agencies, whose work involves psoriasis and psoriatic arthritis related co-morbidities.
- Requires a report to Congress – not later than 180 days after the convening of summit.

SECTION 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE

- Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following:
 - (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis;
 - (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to, cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis; and
 - (3) Health plan and insurer coverage policies, including life-time caps, and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

SECTION 8. AUTHORIZATION OF APPROPRIATIONS.

- Authorizes to be appropriated such sums as may be necessary for each of fiscal years 2010 through 2014.